Saluda Medical Europe Limited (United Kingdom)

Saluda Medical Europe Limited (United Kingdom) is the British entity of Saluda Medical, a neuromodulation company that develops spinal cord stimulation (SCS) technology for chronic pain. The company is headquartered in Harrogate, United Kingdom, and operates as part of the wider Saluda Medical group, whose commercial and clinical activities span the United States, Europe and Australia. Its flagship offering is the Evoke® System, a closed-loop SCS platform that directly records the spinal cord's physiologic response to stimulation using Evoked Compound Action Potentials (ECAPs). Saluda Medical describes itself as pioneering sensing technology since 2010, and states that in 2011 it sensed and recorded the spinal cord's response to stimulation (an ECAP) for the first time. The Evoke® System was built on more than 15 years of research and clinical experience, according to the company, and is positioned as the first SCS system that objectively senses, measures and adjusts on every pulse — an approach the company markets as "removing guesswork" from pain treatment. The company's clinical evidence base includes the landmark EVOKE Study, more than 37 publications and over 200 scientific presentations, with long-term relief reported out to 36 months and trillions of ECAPs recorded in what Saluda describes as the world's largest database of its kind. Saluda Medical frames its mission as disrupting pain "one patient, one pulse at a time," and its stated purpose is to empower people with chronic pain to live freely again. As a UK-registered company based in Harrogate, Saluda Medical Europe Limited supports the group's European commercial and clinical operations. The parent organization, Saluda Medical Pty Ltd, is privately held and was founded in 2010. The UK entity is therefore best understood as a regional subsidiary of a global neuromodulation business rather than a standalone consumer brand.

Saluda Medical was founded in 2010 with the ambition of applying sensing technology to neuromodulation. According to the company, in 2011 it achieved a first: sensing and recording the spinal cord's response to stimulation, known as an Evoked Compound Action Potential (ECAP). This breakthrough became the foundation of the company's closed-loop spinal cord stimulation approach. Over the following decade, Saluda Medical invested in research, development and clinical experience that it says now exceeds 15 years. The company developed the Evoke® System, which it describes as the first SCS system that directly records the spinal cord's physiologic response to stimulation using ECAPs and adjusts stimulation on every pulse. The system was evaluated in the landmark EVOKE Study, and the company reports more than 37 publications and over 200 scientific presentations supporting the technology, with long-term relief demonstrated out to 36 months and trillions of ECAPs recorded. Saluda Medical Europe Limited is the UK-registered entity of the group, based in Harrogate, United Kingdom. It forms part of Saluda Medical's international footprint, which includes operations and commercial activity in the United States, Europe and Australia. The parent company, Saluda Medical Pty Ltd, remains privately held. The UK entity supports the group's mission to disrupt the chronic pain market by replacing uncertainty with confidence through objective, sensing-based spinal cord stimulation.

• 2011

  Saluda Medical senses and records the spinal cord's response to stimulation (an ECAP) for the first time.

• 2010

  Saluda Medical founded; company states it has pioneered sensing technology since 2010.

• Evoke® System developed on 15+ years of research and clinical experience.

• Landmark EVOKE Study and 37+ publications support the Evoke® System.

Closed-loop spinal cord stimulation that objectively senses, measures and adjusts on every pulse, marketed as removing guesswork from chronic pain treatment.

• Evoke® System

  Closed-loop spinal cord stimulation system that senses, measures and adjusts stimulation on every pulse using Evoked Compound Action Potentials (ECAPs).

1. 1Homepage - Saluda Medical USsaludamedical.com
2. 2About Us | Saluda Medicalsaludamedical.com
3. 3Our Story and About Us | Saluda Medicalsaludamedical.com
4. 4Saluda Medical Europe Limited (United Kingdom) - Wikidatawikidata.org